Get the Stockscreener App
7.13
0.56%
-0.04
After Hours:
7.13
Entrada Therapeutics Inc stock is traded at $7.13, with a volume of 341.73K.
It is down -0.56% in the last 24 hours and down -1.52% over the past month.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
See More
Previous Close:
$7.17
Open:
$7.11
24h Volume:
341.73K
Relative Volume:
0.99
Market Cap:
$277.62M
Revenue:
$5.74M
Net Income/Loss:
$-166.12M
P/E Ratio:
-1.7835
EPS:
-3.9978
Net Cash Flow:
$-131.64M
1W Performance:
+1.86%
1M Performance:
-1.52%
6M Performance:
-42.96%
1Y Performance:
+36.59%
1-Day Range:
$7.00
$7.17
1-Week Range:
$6.76
$7.4228
52-Week Range:
$5.02
$16.45
Entrada Therapeutics Inc Stock (TRDA) Company Profile
Name
Entrada Therapeutics Inc
Sector
Industry
Phone
857-305-1825
Address
ONE DESIGN CENTER PLACE, BOSTON
Compare TRDA vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TRDA
Entrada Therapeutics Inc
|
7.13 | 295.92M | 5.74M | -166.12M | -131.64M | -3.9978 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Entrada Therapeutics Inc Stock (TRDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-01-26 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-11-26 | Initiated | Guggenheim | Buy |
| Jan-28-26 | Initiated | Oppenheimer | Outperform |
| Dec-06-24 | Initiated | ROTH MKM | Buy |
| Jan-05-24 | Initiated | Oppenheimer | Outperform |
| Apr-03-23 | Initiated | H.C. Wainwright | Buy |
View All
Entrada Therapeutics Inc Stock (TRDA) Latest News
MPM BIOVENTURES 2018, L.P. Disposes 86,482 Shares of Entrada Therapeutics Between September 1-3, 2026 - Kalkine Media
Entrada Therapeutics' R&D President Sethuraman Natarajan Forfeits 2,079 Shares at $7.14 Each on September 2, 2026 - Kalkine Media
Entrada Therapeutics CFO Wentworth Kory James Forfeits 1,733 Shares at $7.14 Each (NASDAQ: TRDA) - Kalkine Media
TRDAEntrada Therapeutics Inc Revenue Breakdown - Finviz
Mpm Bioventures, 10% owner, sells $617k in Entrada Therapeutics By Investing.com - Investing.com Nigeria
Mpm Bioventures 2018 sells $617k Entrada Therapeutics shares By Investing.com - Investing.com Nigeria
Mpm Bioventures, 10% owner, sells $617k in Entrada Therapeutics - Investing.com
Institutional holder sells Entrada (NASDAQ: TRDA) shares over three days - Stock Titan
MPM funds sell Entrada (TRDA) shares without 10b5-1 plan - Stock Titan
Entrada Therapeutics (TRDA) CEO sale is tax-driven, still owns 517,290 shares - Stock Titan
Automatic tax sale trims Entrada Therapeutics (TRDA) CFO stake - Stock Titan
Automatic tax sale trims Entrada Therapeutics (TRDA) insider stake - Stock Titan
Automatic tax sale trims Entrada Therapeutics (TRDA) COO holdings - Stock Titan
Oppenheimer Maintains Entrada Therapeutics(TRDA.US) With Buy Rating, Maintains Target Price $23 - Moomoo
Liquidity Mapping Around (TRDA) Price Events - news.stocktradersdaily.com
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Moomoo
Mpm Bioventures 2018 sells $615,777 in Entrada Therapeutics stock By Investing.com - Investing.com Nigeria
Mpm Bioventures 2014 L.P. sells $615,777 of Entrada Therapeutics stock By Investing.com - Investing.com South Africa
Mpm Bioventures 2014 L.P. sells $615,777 of Entrada Therapeutics stock - Investing.com
Entrada Therapeutics (NASDAQ: TRDA) insider sells near $7 a share - Stock Titan
Entrada Therapeutics (TRDA) backer MPM funds sell 86,914 shares around $7 - Stock Titan
We Think Entrada Therapeutics (NASDAQ:TRDA) Needs To Drive Business Growth Carefully - Sahm
Mpm Bioventures 2018 sells $461,545 of Entrada Therapeutics stock By Investing.com - Investing.com Nigeria
Mpm Bioventures sells $461,545 in Entrada Therapeutics stock By Investing.com - Investing.com Australia
Entrada Therapeutics (TRDA) 10% owner sells shares outside a 10b5-1 plan - Stock Titan
Analysts Offer Insights on NA Companies: Rapport Therapeutics, Inc. (RAPP) and SpaceX (SPCX) - The Globe and Mail
Entrada (TRDA) Results Breakdown: Reported EPS Tops Expectations at the Close; Investor Response: Shares Move 2.31% Lower at the CloseShare Repurchase Impact - vinanet.vn
Entrada (TRDA) Earnings Update: Profit Per Share Surpasses Its Benchmark on the Day; Share Move: Shares Move Higher 7.02%Analyst Earnings Estimate - vinanet.vn
Analysts Offer Insights on Healthcare Companies: Neumora Therapeutics, Inc. (NMRA), Celcuity (CELC) and Parabilis Medicines, Inc. (PBLS) - The Globe and Mail
(TRDA) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Entrada Therapeutics Inc (TRDA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
HC Wainwright Analysts Lower Earnings Estimates for TRDA - marketbeat.com
Roth MKM Maintains Entrada Therapeutics(TRDA.US) With Buy Rating, Raises Target Price to $11 - Moomoo
Entrada Therapeutics director Kush Parmar sells $1.08 million in shares By Investing.com - Investing.com India
Major Insider Moves Shake Up Entrada Therapeutics Inc. Stock - TipRanks
Entrada Therapeutics director Kush Parmar sells $1.08 million in shares - Investing.com India
5am Ventures V, L.P. sells $431,829 of Entrada Therapeutics stock By Investing.com - Investing.com South Africa
5am Ventures V, L.P. sells $431,829 of Entrada Therapeutics stock - Investing.com
5AM Ventures V reports Entrada Therapeutics share disposal worth $431,620 - Bitget
Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells $358,371.45 in Stock - MarketBeat
Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Director Sells $358,371.45 in Stock - MarketBeat
Entrada Therapeutics (TRDA): 5AM Ventures-linked funds sell 62,811 shares, retain over 1.09M - Stock Titan
Entrada Therapeutics Inc (TRDA) Stock News Today - TradingKey
Analysts’ Top Healthcare Picks: Insulet (PODD), Entrada Therapeutics Inc (TRDA) - The Globe and Mail
Entrada Therapeutics (NASDAQ:TRDA) Releases Quarterly Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat
Entrada Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Entrada Therapeutics Submits Q2 2026 10-Q Report to SEC - Kalkine Media
Entrada Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Entrada Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Entrada Therapeutics Inc Stock (TRDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Entrada Therapeutics Inc Stock (TRDA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| MPM BioVentures 2014, L.P. | 10% Owner |
Aug 24 '26 |
Sale |
7.34 |
21,623 |
158,713 |
4,359,439 |
| MPM BioVentures 2014, L.P. | 10% Owner |
Aug 26 '26 |
Sale |
7.06 |
14,569 |
102,857 |
4,318,348 |
| MPM BIOVENTURES 2018, L.P. | 10% Owner |
Aug 25 '26 |
Sale |
7.54 |
26,522 |
199,976 |
4,332,917 |
| MPM BIOVENTURES 2018, L.P. | 10% Owner |
Aug 24 '26 |
Sale |
7.34 |
21,623 |
158,713 |
4,359,439 |
| MPM BIOVENTURES 2018, L.P. | 10% Owner |
Aug 26 '26 |
Sale |
7.06 |
14,569 |
102,857 |
4,318,348 |
| PARMAR KUSH | Director |
Aug 10 '26 |
Sale |
7.00 |
92,444 |
647,108 |
2,691,337 |
| PARMAR KUSH | Director |
Aug 07 '26 |
Sale |
6.85 |
52,317 |
358,371 |
2,783,781 |
| PARMAR KUSH | Director |
Aug 06 '26 |
Sale |
7.00 |
10,494 |
73,458 |
2,836,098 |
| 5AM Ventures V, L.P. | 10% Owner |
Aug 07 '26 |
Sale |
6.85 |
52,317 |
358,371 |
2,783,781 |
| 5AM Ventures V, L.P. | 10% Owner |
Aug 06 '26 |
Sale |
7.00 |
10,494 |
73,458 |
2,836,098 |
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):